Iraklis Perysinakis1, Chrysanthi Aggeli2, Gregory Kaltsas3, George N Zografos2. 1. Third Department of Surgery, General Hospital "G. Gennimatas",Athens, Greece. 2. Third Department of Surgery, General Hospital "G. Gennimatas", Athens, Greece. 3. Department of Pathophysiology, National University of Athens, Athens, Greece.
Abstract
OBJECTIVE: Complete surgical resection is the only potentially curative treatment of localized pancreatic neuroendocrine tumors. Unfortunately, a significant proportion of these patients present with unresectable locally advanced tumors or massive metastatic disease. Recently, a new therapeutic approach for this subset of patients has emerged consisting of neoadjuvant therapy followed by surgical exploration in responders. DESIGN: We searched MEDLINE for the purpose of identifying reports regarding neoadjuvant treatment modalities for advanced pancreatic neuroendocrine tumors. RESULTS: We identified 12 studies, the vast majority of which were either case reports or small case series. Treatment options included chemotherapy, radiotherapy, peptide receptor radionuclide therapy, biological agents or various combinations of them. CONCLUSIONS: Increasing evidence supports the application of neoadjuvant protocols in advanced pancreatic neuroendocrine tumors aiming at tumor downsizing, thus rendering curative resection feasible. Given that prospective and controlled randomized clinical trials from high-volume institutions are not feasible, expert panel consensus is needed to define the optimal treatment algorithm.
OBJECTIVE: Complete surgical resection is the only potentially curative treatment of localized pancreatic neuroendocrine tumors. Unfortunately, a significant proportion of these patients present with unresectable locally advanced tumors or massive metastatic disease. Recently, a new therapeutic approach for this subset of patients has emerged consisting of neoadjuvant therapy followed by surgical exploration in responders. DESIGN: We searched MEDLINE for the purpose of identifying reports regarding neoadjuvant treatment modalities for advanced pancreatic neuroendocrine tumors. RESULTS: We identified 12 studies, the vast majority of which were either case reports or small case series. Treatment options included chemotherapy, radiotherapy, peptide receptor radionuclide therapy, biological agents or various combinations of them. CONCLUSIONS: Increasing evidence supports the application of neoadjuvant protocols in advanced pancreatic neuroendocrine tumors aiming at tumor downsizing, thus rendering curative resection feasible. Given that prospective and controlled randomized clinical trials from high-volume institutions are not feasible, expert panel consensus is needed to define the optimal treatment algorithm.
Authors: Laura Prakash; Priya Bhosale; Jordan Cloyd; Michael Kim; Nathan Parker; James Yao; Arvind Dasari; Daniel Halperin; Thomas Aloia; Jeffrey E Lee; Jean Nicolas Vauthey; Jason B Fleming; Matthew H G Katz Journal: J Gastrointest Surg Date: 2016-09-15 Impact factor: 3.452
Authors: Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik Journal: Hepatobiliary Surg Nutr Date: 2020-08 Impact factor: 7.293
Authors: Tiago Nunes da Silva; M L F van Velthuysen; Casper H J van Eijck; Jaap J Teunissen; J Hofland; Wouter W de Herder Journal: Endocrinol Diabetes Metab Case Rep Date: 2018-04-11
Authors: Charlotte M Heidsma; Diamantis I Tsilimigras; Flavio Rocha; Daniel E Abbott; Ryan Fields; George A Poultsides; Clifford S Cho; Alexandra G Lopez-Aguiar; Zaheer Kanji; Alexander V Fisher; Bradley A Krasnick; Kamran Idrees; Eleftherios Makris; Megan Beems; Casper H J van Eijck; Elisabeth J M Nieveen van Dijkum; Shishir K Maithel; Timothy M Pawlik Journal: Cancers (Basel) Date: 2021-05-07 Impact factor: 6.639
Authors: Mingzhan Xue; Alaa Shafie; Talha Qaiser; Nasir M Rajpoot; Gregory Kaltsas; Sean James; Kishore Gopalakrishnan; Adrian Fisk; Georgios K Dimitriadis; Dimitris K Grammatopoulos; Naila Rabbani; Paul J Thornalley; Martin O Weickert Journal: Oncotarget Date: 2017-08-16